$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000143774920010494 Filed on May 13, 2020

Income Statement

Concept	2020 Q2	2020 Q1	2019 Q2
Revenue	$2.279M	$2.880M	$1.924M
YoY Change	18.45%	49.69%	20.02%
Cost Of Revenue	$1.208M	$1.174M	$1.045M
YoY Change	15.6%	12.34%	-10.68%
Gross Profit	$1.071M	$1.706M	$879.0K
YoY Change	21.84%	94.08%	98.42%
Gross Profit Margin	46.99%	59.24%	45.69%
Selling, General & Admin	$1.938M	$1.960M	$1.682M
YoY Change	15.22%	12.39%	-24.91%
% of Gross Profit	180.95%	114.89%	191.35%
Research & Development	$322.0K	$294.0K	$341.0K
YoY Change	-5.57%	-1.67%	-40.18%
% of Gross Profit	30.07%	17.23%	38.79%
Depreciation & Amortization	$43.00K	$45.00K	$49.00K
YoY Change	-12.24%	-4.26%	63.33%
% of Gross Profit	4.01%	2.64%	5.57%
Operating Expenses	$2.260M	$2.254M	$2.023M
YoY Change	11.72%	10.38%	-27.75%
Operating Profit	-$1.189M	-$548.0K	-$1.144M
YoY Change	3.93%	-52.88%	-51.46%
Interest Expense	$1.000K	$3.000K	$49.00K
YoY Change	-97.96%	-91.18%	390.0%
% of Operating Profit
Other Income/Expense, Net		$3.000K	$0.00
YoY Change		-91.67%
Pretax Income	-$1.188M	-$545.0K	-$1.095M
YoY Change	8.49%	-51.64%	-53.6%
Income Tax
% Of Pretax Income
Net Earnings	-$1.188M	-$545.0K	-$1.095M
YoY Change	8.49%	-51.64%	-53.27%
Net Earnings / Revenue	-52.13%	-18.92%	-56.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$17.45K	-$8.067K	-$16.26K
COMMON SHARES
Basic Shares Outstanding	67.65M		67.34M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q2	2020 Q1	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.392M	$2.405M	$5.326M
YoY Change	-55.09%	-62.37%	55.28%
Cash & Equivalents	$2.392M	$2.405M	$5.326M
Short-Term Investments			$0.00
Other Short-Term Assets	$27.00K	$587.0K	$27.00K
YoY Change	0.0%	50.51%	-6.9%
Inventory	$645.0K	$580.0K	$530.0K
Prepaid Expenses
Receivables	$2.044M	$2.147M	$1.154M
Other Receivables	$31.00K	$0.00	$86.00K
Total Short-Term Assets	$5.507M	$5.719M	$7.315M
YoY Change	-24.72%	-32.17%	34.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.735M	$1.744M	$1.609M
YoY Change	7.83%	11.51%	22.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$138.0K	$133.0K	$162.0K
YoY Change	-14.81%	-16.88%	-18.18%
Total Long-Term Assets	$3.192M	$3.243M	$2.107M
YoY Change	51.5%	50.98%	4.88%
TOTAL ASSETS
Total Short-Term Assets	$5.507M	$5.719M	$7.315M
Total Long-Term Assets	$3.192M	$3.243M	$2.107M
Total Assets	$8.699M	$8.962M	$9.422M
YoY Change	-7.67%	-15.28%	26.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$654.0K	$937.0K	$683.0K
YoY Change	-4.25%	-6.39%	-50.86%
Accrued Expenses	$921.0K	$807.0K	$438.0K
YoY Change	110.27%	127.97%	-0.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.575M	$1.744M	$1.121M
YoY Change	40.5%	28.71%	-38.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.401M	$1.400M	$621.0K
YoY Change	125.6%	128.38%	5.25%
Total Long-Term Liabilities	$1.401M	$1.400M	$621.0K
YoY Change	125.6%	128.38%	5.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.575M	$1.744M	$1.121M
Total Long-Term Liabilities	$1.401M	$1.400M	$621.0K
Total Liabilities	$2.976M	$3.144M	$1.742M
YoY Change	70.84%	59.76%	-28.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$87.94M	-$86.75M	-$84.49M
YoY Change	4.08%	4.02%	6.48%
Common Stock	$93.66M	$92.57M	$92.17M
YoY Change	1.62%	0.61%	9.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.723M	$5.818M	$7.680M
YoY Change
Total Liabilities & Shareholders Equity	$8.699M	$8.962M	$9.422M
YoY Change	-7.67%	-15.28%	26.38%

Cashflow Statement

Concept	2020 Q2	2020 Q1	2019 Q2
OPERATING ACTIVITIES
Net Income	-$1.188M	-$545.0K	-$1.095M
YoY Change	8.49%	-51.64%	-53.27%
Depreciation, Depletion And Amortization	$43.00K	$45.00K	$49.00K
YoY Change	-12.24%	-4.26%	63.33%
Cash From Operating Activities	-$848.0K	-$862.0K	-$985.0K
YoY Change	-13.91%	-35.58%	-32.07%
INVESTING ACTIVITIES
Capital Expenditures	-$39.00K	-$44.00K	-$105.0K
YoY Change	-62.86%	-65.62%	-19.23%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$2.344M
YoY Change	-100.0%	-100.0%	77.58%
Cash From Investing Activities	-$39.00K	-$44.00K	$2.239M
YoY Change	-101.74%	-102.0%	86.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	874.0K	131.0K	13.00K
YoY Change	6623.08%	-1555.56%	-97.29%
NET CHANGE
Cash From Operating Activities	-848.0K	-862.0K	-985.0K
Cash From Investing Activities	-39.00K	-44.00K	2.239M
Cash From Financing Activities	874.0K	131.0K	13.00K
Net Change In Cash	-13.00K	-775.0K	1.267M
YoY Change	-101.03%	-190.33%	450.87%
FREE CASH FLOW
Cash From Operating Activities	-$848.0K	-$862.0K	-$985.0K
Capital Expenditures	-$39.00K	-$44.00K	-$105.0K
Free Cash Flow	-$809.0K	-$818.0K	-$880.0K
YoY Change	-8.07%	-32.4%	-33.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67650547
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Security12b Title Security12bTitle	Common stock, $0.001
	dei	Trading Symbol TradingSymbol	isr
CY2020Q1	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	260000
CY2019Q2	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	89000
CY2019Q3	isr	Aro Discount Amount Interest Rate AroDiscountAmountInterestRate	5.1
CY2019Q3	isr	Aro Original Obligation Amount AroOriginalObligationAmount	704000
CY2019Q3	isr	Asset Retirement Obligation After Adjustment AssetRetirementObligationAfterAdjustment	555000
CY2019Q3	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	73000
	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	73000
	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
CY2020Q1	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
CY2019Q1	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	171000
	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-117000
	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	-88000
	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	40000
	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	41000
	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-41000
	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued
	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued	163000
CY2015Q4	isr	Purchase Agreement Period PurchaseAgreementPeriod	P1Y
CY2020Q1	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
CY2019Q1	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	45000
CY2020Q1	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	294000
CY2019Q1	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	299000
	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	804000
	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1088000
CY2020Q1	isr	Restocking Fee Percentage RestockingFeePercentage	0.5
CY2020Q1	isr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	0
CY2019Q1	isr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	7000
	isr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	14000
	isr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	94000
CY2020Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	937000
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683000
CY2020Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	45000
CY2019Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	133000
CY2020Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	183000
CY2019Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	142000
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7484000
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7370000
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	92500000
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	92105000
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	29000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	8000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	91000
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	79000
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	37000
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	93000
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	97000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91000
CY2019Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91000
CY2018Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	116000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	276000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	269000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10506000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10064000
CY2019Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	621000
CY2018Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	590000
CY2020Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	570000
CY2019Q1	us-gaap	Asset Retirement Obligation AssetRetirementObligation	613000
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	22000
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	23000
CY2020Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	570000
CY2019Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	621000
CY2020Q1	us-gaap	Assets Assets	8962000
CY2019Q2	us-gaap	Assets Assets	9422000
CY2020Q1	us-gaap	Assets Current AssetsCurrent	5719000
CY2019Q2	us-gaap	Assets Current AssetsCurrent	7315000
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2405000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5326000
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4059000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5507000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2781000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2586000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4240000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2921000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1459000
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5830000
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67650547
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67388047
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67650547
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67388047
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	68000
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	67000
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1174000
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1045000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3348000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3222000
	us-gaap	Depreciation Depreciation	113000
	us-gaap	Depreciation Depreciation	100000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	362000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P310D
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1000
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	24000
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	24000
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1155000
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1099000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3323000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3173000
CY2020Q1	us-gaap	Gross Profit GrossProfit	1706000
CY2019Q1	us-gaap	Gross Profit GrossProfit	879000
	us-gaap	Gross Profit GrossProfit	4053000
	us-gaap	Gross Profit GrossProfit	2168000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	258000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-390000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	993000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-76000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-37000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	13000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	28000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	283000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	53000
CY2019Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	333000
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	198000
CY2019Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	166000
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	34000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	29000
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13000
CY2019Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	31000
CY2020Q1	us-gaap	Inventory Net InventoryNet	580000
CY2019Q2	us-gaap	Inventory Net InventoryNet	530000
CY2020Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	126000
CY2019Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	155000
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	369000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	59000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1179000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	237000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	290000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	290000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	290000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	72000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	117000
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q1	us-gaap	Liabilities Liabilities	3144000
CY2019Q2	us-gaap	Liabilities Liabilities	1742000
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8962000
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9422000
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1744000
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1121000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7361000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-248000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1838000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2793000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4064000
	us-gaap	Net Income Loss NetIncomeLoss	-2258000
	us-gaap	Net Income Loss NetIncomeLoss	-4049000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1508000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-1414000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-1127000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-816000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-897000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-545000
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-548000
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1130000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2266000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4057000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	353000
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3000
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	61000
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	2254000
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	2042000
	us-gaap	Operating Expenses OperatingExpenses	6340000
	us-gaap	Operating Expenses OperatingExpenses	6278000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-548000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1163000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2287000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4110000
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	73000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	220000
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1062000
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	232000
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	830000
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1059000
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y36D
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	133000
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	162000
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	87000
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	74000
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	8000
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	11141000
CY2020Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3000
CY2019Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	8000
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8979000
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1744000
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	587000
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	305000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7370000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	24000
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	9632000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	131000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9228000
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1609000
CY2020Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	2147000
CY2019Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1154000
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294000
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	299000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	804000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1133000
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-86750000
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84492000
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2880000
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1924000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7401000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5390000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1228000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26250
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	70750
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	805000
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	645000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2286000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1996000
	us-gaap	Share Based Compensation ShareBasedCompensation	276000
	us-gaap	Share Based Compensation ShareBasedCompensation	269000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2800000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.75
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	83000
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	83000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	21250
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	10000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	29500
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	20000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	40000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	262500
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	172000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4367000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.65
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	63000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	172000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4367000
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.65
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y65D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y153D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y65D
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	262500
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6900
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	262500
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6900
CY2018Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7494000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	5818000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	7680000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	5030000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	11109000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	9665000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	8611000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	6955000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6141000
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67558000
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67333000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67444000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66937000

Files In Submission

Name	View Source	Status
0001437749-20-010494-index-headers.html	Edgar Link	pending
0001437749-20-010494-index.html	Edgar Link	pending
0001437749-20-010494.txt	Edgar Link	pending
0001437749-20-010494-xbrl.zip	Edgar Link	pending
ex_181375.htm	Edgar Link	pending
ex_181376.htm	Edgar Link	pending
ex_181377.htm	Edgar Link	pending
ex_181378.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20200331.xml	Edgar Link	completed
isr-20200331.xsd	Edgar Link	pending
isr-20200331_cal.xml	Edgar Link	unprocessable
isr-20200331_def.xml	Edgar Link	unprocessable
isr-20200331_lab.xml	Edgar Link	unprocessable
isr-20200331_pre.xml	Edgar Link	unprocessable
isr20200331_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2020 Q2 Form 10-Q Financial Statement

#000143774920010494 Filed on May 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2020 Q2 Form 10-Q Financial Statement

#000143774920010494 Filed on May 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx